KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Capital Leases: 2012-2013

Historic Capital Leases for Halozyme Therapeutics (HALO) over the last 1 years, with Sep 2013 value amounting to $2.5 million.

  • Halozyme Therapeutics' Capital Leases was N/A to $2.5 million in Q3 2013 from the same period last year, while for Sep 2013 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2012, which is N/A change from last year.
  • Halozyme Therapeutics' Capital Leases amounted to $2.5 million in Q3 2013, which was up 21.43% from $2.1 million recorded in Q2 2013.
  • In the past 5 years, Halozyme Therapeutics' Capital Leases ranged from a high of $2.5 million in Q3 2013 and a low of $1.4 million during Q4 2012.
  • Over the past 2 years, Halozyme Therapeutics' median Capital Leases value was $1.8 million (recorded in 2012), while the average stood at $1.9 million.